The District of Columbia Alcoholic Beverage and Cannabis Board has imposed a 30-day suspension on KLM, LLC, operating as Doobie District on U Street, for dispensing medical cannabis to unqualified buyers and falsifying records in the state's METRC tracking system. Issued on February 11, 2026, in Order No. 2026-211, this action underscores the Board's commitment to safeguarding the medical cannabis program's integrity amid rising compliance challenges in the District's evolving market.
Investigation Reveals Serious Compliance Failures
An ABCA probe launched May 9, 2025, exposed Doobie District's lapses after tips about unauthorized sales. Undercover agents made two controlled buys at 1526 U Street NW, purchasing medical cannabis without showing patient cards or caregiver credentials. Labels on the products bizarrely listed a staff member's name and ID, not the buyers'.
Further scrutiny showed the employee's METRC account exceeded DC's strict 8-ounce, 30-day patient limit, with two other accounts similarly oversold using the same credentials. METRC, the seed-to-sale system, is crucial for tracing products from cultivation to consumption, preventing diversion to illicit markets—a persistent issue in cannabis regulation nationwide.
- Charge 1: Dispensing to non-qualified patients/caregivers (22-C DCMR § 5709.5)
- Charge 2: Entering false METRC data (22-C DCMR § 5615.3)
Licensee's Defense and Board's Rationale
Owner Peter Murillo admitted the facts at a show cause hearing, blaming rogue employees who were fired and retrained. New measures include personal oversight of sales and volumes. Despite these steps, the Board stressed licensee accountability for supervision, considering but rejecting revocation due to lack of direct owner knowledge.
The 30-day medical retailer license suspension begins soon, plus mandatory ABCA-approved training within 60 days. Non-compliance risks re-suspension. This balanced penalty reflects a pattern: DC's medical program, operational since 2011, enforces limits to prioritize patient health over profit, contrasting looser recreational rules.
Implications for DC's Cannabis Landscape
These violations highlight vulnerabilities in DC's dual medical-recreational framework, where medical products demand verification to protect vulnerable patients and curb underage or recreational diversion. With oversales mimicking black-market tactics, such infractions erode public trust and fuel health risks like unintended potency exposure.
Broader trends show U.S. states tightening tracking post-legalization; DC's actions align with data from similar markets, where non-compliance correlates with 20-30% higher diversion rates per federal estimates. For consumers, this reinforces choosing verified dispensaries; for the industry, it's a reminder that robust internal controls are non-negotiable amid $3 billion+ annual U.S. medical sales growth.
